13 listed sites: United States (13) - 15 Nov `24TEV-53408 antibody treatment for nonsegmental vitiligo

TEV-53408 antibody treatment for nonsegmental vitiligo

Official title: A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo

Status: Closed to new participants

Description:

Teva Branded Pharmaceutical Products R&D LLC plans to enroll about 66 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 75 may qualify. The study is underway but is no longer accepting new participants.

Start date: November 11, 2024

Completion date: January 31, 2029

Organizer: Teva Branded Pharmaceutical Products R&D LLC

Contact: Teva Medical Expert, MD

Link: https://clinicaltrials.gov/study/NCT06625177

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference TEV-53408 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Which therapy has minimal side-effects?

    Dead Sea climatotherapy is a unique and highly effective treatment option for vitiligo, offering a top-tier safety profile and natural therapeutic benefits. Its combination of p...

  • Is there a traditional medicine to treat vitiligo?

    Traditional remedies can be helpful for managing stress or general metabolic health, but when it comes to vitiligo, the evidence is limited. While some natural supplements provi...

  • Can Ayurveda help with vitiligo?

    Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...